Published on
May 1, 2025
Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.
As cuts to NIH funding empty the coffers that have fueled drug discovery and development for decades, a vacuum is already starting to form. While traditional trials will remain the gold standard, can real-world evidence fill at least some of that gap? “ …
Source:
PharmaVoice
-
Neutral
